查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1800960

多发性硬化症治疗市场报告（按药物、药物类型、给药途径、配销通路和地区）2025 年至 2033 年

Multiple Sclerosis Therapies Market Report by Drug, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

2024 年全球多发性硬化症治疗市场规模达 279 亿美元。展望未来， IMARC Group预计到 2033 年市场规模将达到 388 亿美元，2025-2033 年期间的成长率 (CAGR) 为 3.52%。

多发性硬化症 (MS) 是一种慢性发炎性免疫介导疾病，可导致脊髓和脑神经细胞脱髓鞘、轴突断裂和神经退化。一些常用的治疗方法包括注射、口服和输液药物、肌肉鬆弛剂、抗忧郁药物以及物理治疗。注射药物，如干扰素β和醋酸格拉替雷，可透过皮下或肌肉注射；口服药物包括富马酸二甲酯、特立氟胺和克拉屈滨；输液治疗包括奥瑞珠单抗、那他珠单抗和阿崙单抗，可经由静脉注射。这些药物有助于控制症状，最大限度地减少復发频率，并控制患者的心率和血压。

全球復发缓解型多发性硬化症 (RRMS)、原发性进展型多发性硬化症 (PPMS)、继发进展型多发性硬化症 (SPMS) 和进展復发型多发性硬化症 (PRMS) 的盛行率不断上升，是推动市场成长的关键因素之一。此外，老年人口的不断增长也为市场成长提供了动力，老年人更容易患上此类疾病。医疗保健提供者正在广泛使用免疫抑制剂来控制自体免疫攻击并防止多发性硬化症患者復发。此外，各种技术进步，例如开髮用于有效治疗多发性硬化症的创新单株抗体、免疫调节剂、免疫抑制剂和干扰素，也是其他重要的成长诱导因素。此外，已开发国家和新兴国家的政府都在进行宣传活动，以提高民众对现有治疗替代方案的认识，这反过来又为市场创造了积极的前景。其他因素，包括广泛的研究和开发 (R&D) 活动以及医疗保健基础设施的改善，预计将进一步推动市场发展。

本报告回答的关键问题：

  • 全球多发性硬化症治疗市场迄今表现如何？未来几年将如何表现？
  • COVID-19 对全球多发性硬化症治疗市场有何影响？
  • 主要的区域市场有哪些？
  • 根据药品的不同，市场分布如何？
  • 根据药物类型，市场是如何分類的？
  • 根据行政路径，市场如何划分？
  • 根据配销通路，市场如何划分？
  • 该产业的价值链分为哪些阶段？
  • 该行业的主要驱动因素和挑战是什么？
  • 全球多发性硬化症治疗市场的结构是怎么样的？主要参与者是谁？
  • 产业竞争程度如何？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球多发性硬化症治疗市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依药物

  • 免疫调节剂
    • 主要类型
      • 克帕松
      • Avonex/Plegridy
      • 吉尔尼亚
      • 泰萨布里
      • 倍他塞隆/Extavia
      • 特西菲德拉
      • 利比
      • 安比拉
  • 免疫抑制剂
    • 主要类型
      • 奥巴吉奥
      • 莱姆特拉达
      • 奥瑞珠单抗
      • 百日草

第七章：市场区隔：依药物类型

  • 生物药物
  • 小分子药物

第八章：市场区隔：依行政途径

  • 口服
  • 注射剂
  • 静脉

第九章：市场区隔：按配销通路

  • 医院药房
  • 零售药局
  • 网路药局

第十章：市场细分：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 11 章：SWOT 分析

第 12 章：价值链分析

第 13 章：波特五力分析

第 14 章：价格分析

第 15 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbvie Inc.
    • Bayer Aktiengesellschaft
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG (Roche Holding AG)
    • GlaxoSmithKline Plc
    • Merck & Co. Inc.
    • Novartis AG
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112025A2571

The global multiple sclerosis therapies market size reached USD 27.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 38.8 Billion by 2033, exhibiting a growth rate (CAGR) of 3.52% during 2025-2033.

Multiple sclerosis (MS) refers to a chronic and inflammatory immune-mediated condition that can cause demyelination, axonal transection and neurodegeneration of the nerve cells in the spinal cord and brain. Some of the commonly used therapies include the administration of injectable, oral and infused medicines, muscle relaxants, antidepressants and physical therapy. The injectable medication, such as Interferon-beta and Glatiramer acetate, are administered under the skin or into the muscle; oral medications include Dimethyl fumarate, Teriflunomide and Cladribine; and infusion treatments include Ocrelizumab, Natalizumab and Alemtuzumab, which are administered intravenously. These medicines aid in managing the symptoms to minimize the frequency of the relapses and control the heart rate and blood pressure of the patient.

The increasing prevalence of relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) across the globe, is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Healthcare providers are widely using immunosuppressants that control autoimmune attacks and prevent relapses among patients suffering from MS. Additionally, various technological advancements, such as the development of innovative monoclonal bodies, immunomodulators, immunosuppressants and interferons for the effective treatment of MS, are acting as other major growth-inducing factors. Apart from this, governments of both the developed and emerging countries are launching campaigns to increase awareness regarding the available treatment alternatives among the masses, which, in turn, is creating a positive outlook for the market. Other factors, including extensive research and development (R&D) activities, along with the improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

Breakup by Drug:

  • Immunomodulators
    • Copaxone
    • Avonex/Plegridy
    • Gilneya
    • Tysabri
    • Betaseron/Extavia
    • Tecifidera
    • Rebif
    • Ampyra
  • Immunosuppressants
    • Aubagio
    • Lemtrada
    • Ocrelizumab
    • Zinbryta

Breakup by Drug Type:

  • Biologic Drugs
  • Small Molecule Drugs

Breakup by Route of Administration:

  • Oral
  • Injectable
  • Intravenous

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., Bayer Aktiengesellschaft, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Sanofi S.A. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global multiple sclerosis therapies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global multiple sclerosis therapies market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global multiple sclerosis therapies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Multiple Sclerosis Therapies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug

  • 6.1 Immunomodulators
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Copaxone
      • 6.1.2.2 Avonex/Plegridy
      • 6.1.2.3 Gilneya
      • 6.1.2.4 Tysabri
      • 6.1.2.5 Betaseron/Extavia
      • 6.1.2.6 Tecifidera
      • 6.1.2.7 Rebif
      • 6.1.2.8 Ampyra
    • 6.1.3 Market Forecast
  • 6.2 Immunosuppressants
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Aubagio
      • 6.2.2.2 Lemtrada
      • 6.2.2.3 Ocrelizumab
      • 6.2.2.4 Zinbryta
    • 6.2.3 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Biologic Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Small Molecule Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Intravenous
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbvie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Bayer Aktiengesellschaft
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Biogen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Bristol-Myers Squibb Company
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 SWOT Analysis
    • 15.3.6 GlaxoSmithKline Plc
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck & Co. Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Novartis AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Sanofi S.A.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Multiple Sclerosis Therapies Market: Major Drivers and Challenges
  • Figure 2: Global: Multiple Sclerosis Therapies Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Multiple Sclerosis Therapies Market: Breakup by Drug (in %), 2024
  • Figure 4: Global: Multiple Sclerosis Therapies Market: Breakup by Drug Type (in %), 2024
  • Figure 5: Global: Multiple Sclerosis Therapies Market: Breakup by Route of Administration (in %), 2024
  • Figure 6: Global: Multiple Sclerosis Therapies Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Multiple Sclerosis Therapies Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 9: Global: Multiple Sclerosis Therapies (Immunomodulators) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Multiple Sclerosis Therapies (Immunomodulators) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Multiple Sclerosis Therapies (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Multiple Sclerosis Therapies (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Multiple Sclerosis Therapies (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Multiple Sclerosis Therapies (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Multiple Sclerosis Therapies (Intravenous) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Multiple Sclerosis Therapies (Intravenous) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: North America: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: North America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: United States: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: United States: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Canada: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Canada: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Asia Pacific: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Asia Pacific: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: China: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: China: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Japan: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Japan: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: India: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: India: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: South Korea: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: South Korea: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Australia: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Australia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Indonesia: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Indonesia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Europe: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Europe: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Germany: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Germany: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: France: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: France: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: United Kingdom: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: United Kingdom: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Italy: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Italy: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Spain: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Spain: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Russia: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Russia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Latin America: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Latin America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Brazil: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Brazil: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Mexico: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Mexico: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Middle East and Africa: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Middle East and Africa: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Multiple Sclerosis Therapies Industry: SWOT Analysis
  • Figure 78: Global: Multiple Sclerosis Therapies Industry: Value Chain Analysis
  • Figure 79: Global: Multiple Sclerosis Therapies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Multiple Sclerosis Therapies Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug (in Million USD), 2025-2033
  • Table 3: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 4: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 5: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 6: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Multiple Sclerosis Therapies Market Structure
  • Table 8: Global: Multiple Sclerosis Therapies Market: Key Player